Roberto Carnevale

Prof. Roberto Carnevale

Universita degli Studi di Roma La Sapienza, Department of Medico-Surgical Sciences and Biotechnologies, Roma, Italy
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in Chest
Verified
Journal Article
Closed access
Roberto CarnevaleRoberto Carnevale
Roberto Carnevale
SSSebastiano Sciarretta
Sebastiano Sciarretta
FVFrancesco Violi
Francesco Violi
Cristina NocellaCristina Nocella
Cristina Nocella
Lorenzo LoffredoLorenzo Loffredo
Lorenzo Loffredo
Giacomo FratiGiacomo Frati
Giacomo Frati

8 June 2020 in Nutrients
Verified
Journal Article
Open access
PDF file
FIFabio Infusino
Fabio Infusino
MMMassimiliano Marazzato
Massimiliano Marazzato
MMMassimo Mancone
Massimo Mancone
FFFrancesco Fedele
Francesco Fedele
CMClaudio Mastroianni
Claudio Mastroianni
Gabriella d'EttorreGabriella d'Ettorre
Gabriella d'Ettorre
The severe acute respiratory syndrome coronavirus 2 (Sars-CoV-2) global pandemic is a devastating event that is causing thousands of victims every day around the world. One of the main reasons of the great impact of coronavirus disease 2019 (COVID-19) on society is its unexpected spread, which has not allowed an adequate preparation. The scientific community is fighting against time for the production of a vaccine, but it is difficult to place a safe and effective product on the market as fast as the virus is spreading. Similarly, for drugs that can directly interfere with viral pathways, their production times are long, despite the great efforts made. For these reasons, we analyzed the possible role of non-pharmacological substances such as supplements, probiotics, and nutraceuticals in reducing the risk of Sars-CoV-2 infection or mitigating the symptoms of COVID-19. These substances could have numerous advantages in the current circumstances, are generally easily available, and have negligible side effects if administered at the already used and tested dosages. Large scientific evidence supports the benefits that some bacterial and molecular products may exert on the immune response to respiratory viruses. These could also have a regulatory role in systemic inflammation or endothelial damage, which are two crucial aspects of COVID-19. However, there are no specific data available, and rigorous clinical trials should be conducted to confirm the putative benefits of diet supplementation, probiotics, and nutraceuticals in the current pandemic.

19 March 2019 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
Giuseppe Biondi-ZoccaiGiuseppe Biondi-Zoccai
Giuseppe Biondi-Zoccai
SSSebastiano Sciarretta
Sebastiano Sciarretta
CBChristopher Bullen
Christopher Bullen
CNCristina Nocella
Cristina Nocella
FVFrancesco Violi
Francesco Violi
GFGiacomo Frati
Giacomo Frati
Background: Little clinical research on new‐generation heat‐not‐burn cigarettes ( HNBC ) in comparison with electronic vaping cigarettes ( EVC ) and traditional tobacco combustion cigarettes ( TC ) has been reported. We aimed to appraise the acute effects of single use of HNBC , EVC, and TC in healthy smokers. Methods and Results: This was an independent, cross‐over, randomized trial in 20 TC smokers, with allocation to different cycles of HNBC , EVC , and TC . All participants used all types of products, with an intercycle washout of 1 week. End points were oxidative stress, antioxidant reserve, platelet activation, flow‐mediated dilation, blood pressure, and satisfaction scores. Single use of any product led to an adverse impact on oxidative stress, antioxidant reserve, platelet function, flow‐mediated dilation, and blood pressure. HNBC had less impact than EVC and TC on soluble Nox2‐derived peptide (respectively, P =0.004 and 0.001), 8‐iso‐prostaglandin F2α‐ III ( P =0.004 and <0.001), and vitamin E ( P =0.018 and 0.044). HNBC and EVC were equally less impactful than TCs on flow‐mediated dilation ( P =0.872 for HNBC versus EVC ), H 2 O 2 ( P =0.522), H 2 O 2 breakdown activity ( P =0.091), soluble CD 40 ligand ( P =0.849), and soluble P‐selectin ( P =0.821). The effect of HNBC and, to a lesser extent EVC , on blood pressure was less evident than that of TC , whereas HNBC appeared more satisfying than EVC (all P <0.05). Conclusions: Acute effects of HNBC , EVC, and TC are different on several oxidative stress, antioxidant reserve, platelet function, cardiovascular, and satisfaction dimensions, with TCs showing the most detrimental changes in clinically relevant features. Clinical Trial Registration: URL : http://www.clinicaltrials.gov . Unique identifier: NCT 03301129.

3 July 2012 in Circulation
Verified
Journal Article
Closed access
PDF file
PPPasquale Pignatelli
Pasquale Pignatelli
Roberto CarnevaleRoberto Carnevale
Roberto Carnevale
Daniele PastoriDaniele Pastori
Daniele Pastori
Roberto CangemiRoberto Cangemi
Roberto Cangemi
LNLaura Napoleone
Laura Napoleone
FVFrancesco Violi
Francesco Violi
Background—: Statins exert an antithrombotic effect in patients at risk of or with acute thrombosis, but no study has investigated whether this effect is immediate and whether there is an underline mechanism. Methods and Results—: Patients with hypercholesterolemia were randomly allocated to a Mediterranean diet with low cholesterol intake (<300 mg/d; n=15) or atorvastatin (40 mg/d; n=15). Oxidative stress, as assessed by serum Nox2 and urinary isoprostanes, and platelet activation, as assessed by platelet recruitment, platelet isoprostanes, and thromboxane A 2 , platelet Nox2, Rac1, p47 phox , protein kinase C, vasodilator-stimulated phosphoprotein, nitric oxide, and phospholipase A 2 , were determined at baseline and after 2, 24, and 72 hours and 7 days of follow-up. An in vitro study was also performed to see whether atorvastatin affects platelet oxidative stress and activation. The atorvastatin-assigned group showed a significant and progressive reduction of urinary isoprostanes and serum Nox2, along with inhibition of platelet recruitment, platelet isoprostanes, Nox2, Rac1, p47 phox , and protein kinase C, starting 2 hours after administration. Platelet phospholipase A 2 and thromboxane A 2 significantly decreased and vasodilator-stimulated phosphoprotein and nitric oxide increased after 24 hours. Low-density lipoprotein cholesterol decreased significantly after 72 hours and further declined after 7 days. No changes were observed in the Mediterranean diet group. In vitro experiments demonstrated that atorvastatin dose-dependently inhibited platelet Nox2 and phospholipase A 2 activation, along with inhibition of platelet recruitment, platelet isoprostanes, and thromboxane A 2 , and increased vasodilator-stimulated phosphoprotein and nitric oxide. Conclusions—: The study provides the first evidence that atorvastatin acutely and simultaneously decreases oxidative stress and platelet activation by directly inhibiting platelet Nox2 and ultimately platelet isoprostanes and thromboxane A 2 . These findings provide a rationale for the use of statins to prevent or modulate coronary thrombosis. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01322711.

1 September 2006 in Atherosclerosis
Verified
Journal Article
Closed access
PPPasquale Pignatelli
Pasquale Pignatelli
AGA. Ghiselli
A. Ghiselli
BBB. Buchetti
B. Buchetti
Roberto CarnevaleRoberto Carnevale
Roberto Carnevale
fausta natellafausta natella
fausta natella
FVFrancesco Violi
Francesco Violi

1 February 2005 in Circulation
Verified
Journal Article
Closed access
PDF file
VSValerio Sanguigni
Valerio Sanguigni
PPPasquale Pignatelli
Pasquale Pignatelli
LLLuisa Lenti
Luisa Lenti
Domenico FerroDomenico Ferro
Domenico Ferro
ABAlfonso Bellia
Alfonso Bellia
FVFrancesco Violi
Francesco Violi
Background— Soluble CD40L (sCD40L), a substance that maximally reflects in vivo platelet activation, is increased in patients with hypercholesterolemia. We investigated the relation between sCD40L and platelet CD4OL in hypercholesterolemic patients before and after a short-term treatment with atorvastatin. Methods and Results— Collagen-induced platelet CD40L and plasma levels of sCD40L and prothrombin fragment F1+2, a marker of thrombin generation, were investigated in 30 hypercholesterolemic patients and 20 healthy subjects. Hypercholesterolemic patients were then randomized to either diet (n=15; group A) or atorvastatin 10 mg/d (group B); the aforementioned variables were measured at baseline and after 3 days of treatment. Compared with referents, hypercholesterolemic patients showed higher values of platelet CD40L ( P <0.005), sCD40L ( P <0.005), and F1+2 ( P <0.003). Platelet CD40L was significantly correlated with sCD40L ( P <0.001), and the latter was significantly correlated with F1+2 ( P <0.001). The intervention trial showed no changes in group A but a significant decrease in platelet CD40L ( P <0.01), sCD40L ( P <0.002), and F1+2 ( P <0.03) in group B. In vitro studies demonstrated that cholesterol enhanced platelet CD40L and CD40L-mediated clotting activation by human monocytes; also, atorvastatin dose-dependently inhibited platelet CD40L expression and clotting activation by CD40L-stimulated monocytes. Conclusions— This study shows that, in hypercholesterolemia, platelet overexpression of CD40L may account for enhanced plasma levels of sCD40L and F1+2. Atorvastatin exerts a direct antithrombotic effect via inhibition of platelet CD40L and CD40L-mediated thrombin generation, independently of its cholesterol-lowering effect.